A Phase 2 Pharmacodynamic Study of Pre-operative Figitumumab in Patients with Localized Prostate Cancer
Clinical Cancer Research, 05/04/2012Chi KN et al.
Figitumumab is biologically active in prostate cancer. PSA declines in treatment naive patients were observed, potentially mediated by insulin–like growth factor 1 receptor (IGF–IR) effects on androgen receptor expression. These results support the clinical relevance of IGF–IR signalling in prostate cancer and justify further clinical trials.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.